EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Metyrapone Treatment Protects Low-Density Lipoprotein Receptor Knockout Mice against Hypercorticosteronemia Development without Changing Atherosclerosis Susceptibility

Ronald J van der Sluis iD, Tim van den Aardweg, Timothy J P Sijsenaar iD, Miranda Van Eck, Menno Hoekstra iD

Biomolecules · 2023

DOI: 10.3390/biom13091287 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2023. Verfasst von Ronald J van der Sluis und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, 2333CC Leiden, The Netherlands. Hauptthemen laut MEDLINE: Metyrapone, Atherosclerosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch Research Council, Dutch Heart Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The steroid 11beta-hydroxylase inhibitor metyrapone is able to effectively reverse the hypercortisolemia detected in human Cushing’s Syndrome patients. In this current preclinical study, we investigated whether metyrapone monotherapy can also reverse the hypercortisolemia-associated increase in atherosclerotic cardiovascular disease risk. In this instance, female low-density lipoprotein receptor knockout mice fed a cholic acid-containing high cholesterol/high fat diet to induce the development of hypercorticosteronemia and atherosclerotic lesions were treated twice daily with 100 mg/kg metyrapone for 4 weeks. Metyrapone effectively protected against hypercorticosteronemia development with endpoint plasma corticosterone levels remaining 43% lower than in controls (p < 0.01). Gene expression analysis in livers and adrenals validated that glucocorticoid receptor signaling was also reduced. Importantly, metyrapone treatment did not impact plasma cholesterol levels or alter atherosclerotic plaque areas or lesional collagen contents. However, metyrapone induced significant systemic lymphocytopenia as evident from marked decreases in splenic white pulp contents and thymus weights (−48% and −41%, respectively; p < 0.001). In conclusion, we have shown that treatment with metyrapone diminishes hypercorticosteronemia without affecting atherosclerosis susceptibility in cholic acid-containing high cholesterol/high fat diet-fed low-density lipoprotein receptor knockout mice. These preclinical findings highlight that restoring plasma glucocorticoid levels to normal is not necessarily sufficient to overcome the cardiovascular co-morbidities associated with human Cushing’s disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetyraponeAtherosclerosisMiceAnimalsHumansFemaleMice, KnockoutCholesterolGlucocorticoidsLipoproteins, LDLCholic AcidMice, Inbred C57BL

Stichwörter der Autor:innen

11beta-hydroxylaseLDL receptor knockout miceatherosclerosiscorticosteroneglucocorticoidlymphocytopeniametyrapone

Substanzen

MetyraponeCholesterolGlucocorticoidsLipoproteins, LDLCholic Acid

Autor:innen und Institutionen

  • Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, 2333CC Leiden, The Netherlands.
  • Division of Systems Pharmacology and Pharmacy, Leiden Academic Centre for Drug Research, Leiden University, 2333CC Leiden, The Netherlands.
  • Pharmacy Leiden, Leiden, The Netherlands.

ORCID-Profile: Ronald J van der Sluis, Timothy J P Sijsenaar, Menno Hoekstra

Förderung

  • Dutch Research Council
  • Dutch Heart Foundation

Zitieren

APA

van der Sluis, R. J., van den Aardweg, T., Sijsenaar, T. J. P., Van Eck, M., & Hoekstra, M. (2023). Metyrapone Treatment Protects Low-Density Lipoprotein Receptor Knockout Mice against Hypercorticosteronemia Development without Changing Atherosclerosis Susceptibility. Biomolecules. https://doi.org/10.3390/biom13091287

Vancouver

van der Sluis RJ, van den Aardweg T, Sijsenaar TJP, Van Eck M, Hoekstra M. Metyrapone Treatment Protects Low-Density Lipoprotein Receptor Knockout Mice against Hypercorticosteronemia Development without Changing Atherosclerosis Susceptibility. Biomolecules. 2023. doi:10.3390/biom13091287

BibTeX
@article{vanderSluis2023,
  author = {van der Sluis, Ronald J and van den Aardweg, Tim and Sijsenaar, Timothy J P and Van Eck, Miranda and Hoekstra, Menno},
  title = {Metyrapone Treatment Protects Low-Density Lipoprotein Receptor Knockout Mice against Hypercorticosteronemia Development without Changing Atherosclerosis Susceptibility},
  journal = {Biomolecules},
  year = {2023},
  doi = {10.3390/biom13091287}
}
Kostenlos starten →